Cann Group Ltd. · ASX:CAN
Cann — Pitt Street Research Life Sciences Conference 2024
18 slides from Cann's conference presentation, Sep 19, 2024
Slide 1: ASX Announcement: Investor presentation
ASX ANNOUNCEMENT 19 September 2024 Investor presentation 19 September 2024 – Cann Group Limited (ASX: CAN) (Cann or the Company) is pleased to provide an investor presentation providing investors with information on the Company’s strategic growth plans and investment opportunity. This presentation s
Slide 2: Pitt Street Research Life Sciences Conference
CANN GROUP LIMITED For personal use only ASX:CAN Pitt Street Research Life Sciences Conference 19 SEPTEMBER 2024 AT T H E F O R E F R O N T O F M E D I C I N A L C A N N A B I S I N A U S T R A L I A S I N C E 2 0 1 7
Slide 3: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann). Summary information This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentation. The information provided in this Pre
Slide 4: Cann Group
For personal use only Cann Group is proud to be the first Australian company to have been issued with a Cannabis CANN GROUP Research Licence and Cannabis Cultivation Licence to grow and produce cannabis for medicinal purposes by the Australian Government’s Office of Drug Control in February and Est.
Slide 5: Mildura facility secures strong competitive advantage
Mildura facility secures strong competitive advantage Cann Group’s Mildura facility is arguably the most technologically advanced indoor, full GMP medicinal cannabis cultivation & manufacturing facility in the southern hemisphere For personal use only • A microclimate-controlled glasshouse with manu
Slide 6: Breeding program
Breeding program First-round of seven shortlisted Cann Group breeding candidates developed in collaboration with Ag-VIC as part of the “CRADA” program are currently in the final stages of commercial assessment at Cann’s Mildura Facility. A selection of these shortlisted candidates became available f
Slide 7: Imported strains
Imported strains For personal use only Cann’s breeding program sits The first import of 17 new strain lots The second import of 20 new strain alongside an aggressive seed has now all completed phenotyping lots has been germinated at Cann’s importation and phenotyping and awaiting final chemotyping N
Slide 8: Botanitech (own-brand) heads up a diverse product range
Botanitech (own-brand) heads up a diverse product range For personal use only Local manufacture and Botanitech dried flower, oil Bulk dried flower Satipharm – CBD, THC & supply of dried flower & and vapes (sold to manufacturers & balanced* capsules featuring oils (white label) compounders) patented
Slide 9: Contract services offered at cGMP facility
Contract services offered at cGMP facility For personal use only Contract growing Contract packing services Contract laboratory services • ODC permit for genetic stock, cultivation and • cGMP manufacturing facility • Onsite cGMP (TGA) certified laboratory production of medicinal cannabis • Licensed
Slide 10: Market overview
Market overview • 2 - 2.4 million Australians use more than 650 tonnes of cannabis each year both legally and illegally • Legal Medicinal Cannabis (MC) market is now exceeding 100 tonnes per year • Current MC value is estimated to be between $500-$700 million at a patient level, growing around 25% Y
Slide 11: Growth drivers
Growth drivers Improved Increasing perception Regulation number of Export & locally & law For personal use only delivery markets grown changes forms quality • Improving perception of • TGA regulation changes • Alternative forms to E.g. role of MC for treating a could restrict cheaper inhalable flowe
Slide 12: Cann poised to seize growing market opportunity
Cann poised to seize growing market opportunity Established Expertise GMP facility customer base & Cutting edge R&D program commercial pathways • Strong knowledge of, and • Full cultivation and GMP • Established pathways to market • Long-term affiliation with reputation with, regulatory manufacturin
Slide 13: FY2024 Highlights
FY2024 HIGHLIGHTS REVENUE PRODUCTION For personal use only $15.73M 4.4 TONNES 11.6% YOY 100% YOY EBITDA LOSS OPERATING EXPENSE RATIO ($13.2M) 128% 24.1% IMPROVEMENT YOY 10% POINTS IMPROVEMENT YOY
Slide 14: FY2025 growth plan to deliver positive EBITDA is underway
FY2025 growth plan to deliver positive EBITDA is underway Maximise margins with Focus on quality Move from 3 cultivars to Enhance non-inhalable Expand Botanitech range efficiencies & cost inhalable flower to meet a 10-12 cultivar portfolio flower product range control market expectations For persona
Slide 15: Path to profitability & beyond
Path to profitability & beyond Increasing production to 10 tonnes per annum by FY2027 will ensure strong revenue growth and profitability at today’s average selling price of $3.45 per gram. Facility expansion into remaining zones will further accelerate revenue growth. DRIED FLOWER WEIGHT (JGS) PROD
Slide 16: Outlook
Outlook Increased revenue opportunity medium term via expansion into Mildura facility additional 8 zones For personal use only Progressing the scale and Extending portfolio range to Continuing our path towards quality of production. Aim to meet market demands, via our EBITDA profitability meet 9-10
Slide 17: Investment highlights
Investment highlights For personal use only Research & development Mildura GMP facility Board & management Local genetic breeding, and seed Cann’s GMP indoor facility has unique Management with multi-industry importation and phenotyping, year-round, multiple production run, & experience and results
Slide 18: Thank you
THANK YOU For personal use only Jenni Pilcher CEO & Managing Director jenni.pilcher@canngrouplimited.com
Cann Group — Pitt Street Research Life Sciences Conference 2024 on 6ix